Abstract:The World Health Organization has declared that the outbreak of coronavirus disease 2019(COVID-19)is a global pandemic.As mutations occurred in the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the global epidemic still needs further concern.Worryingly,the effectiveness and neutralizing activity of existing antibodies and vaccines against SARS-CoV-2 variants is declining.There is an urgent need to find an effective antiviral medication with broad-spectrum inhibitory effects on novel coronavirus mutant strains against the SARS-CoV-2 infection.Neutralizing antibodies play an important role in the prevention and treatment of COVID-19.The interaction of spike-receptor-binding domain(Spike-RBD)of SARS-CoV-2 and human angiotensin-converting enzyme 2(ACE2)is the first and critical step of SARS-CoV-2 infection.Hence,the SARS-CoV-2 Spike-RBD is a hot target for neutralizing antibodies development.Evusheld,the combination of Tixagevimab and Cilgavimab monoclonal antibodies(mAbs)targeting Spike-RBD exhibits neutralizing activity against BA.2.12.1,BA.4 and BA.5,which could be used as pre-exposure prophylaxis against SARS-CoV-2 infection.The nucleocapsid(N)protein is a conservative and high-abundance structural protein of SARS-CoV-2.The nCoV396 monoclonal antibody,isolated from the blood of convalescent COVID-19 patients against the N protein of SARS-CoV-2.This mAb not only showed neutralizing activity but also inhibits hyperactivation of complement and lung injury induced by N protein.The mAb 3E8 targeting ACE2 showed broadly neutralizing activity against SARS-CoV-2 and D614G,B.1.1.7,B.1.351,B.1.617.1 and P.1 variants in vitro and in vivo,but did not impact the biological activity of ACE2.Compared with neutralizing antibodies,small molecule inhibitors have several advantages,such as broad-spectrum inhibitory effect,low cost,and simple administration methods.Several small-molecule inhibitors disrupt viral binding by targeting the ACE2 and N-terminal domain(NTD)of SARS-CoV-2 spike protein.Known drugs such as chloroquine and hydroxychloroquine could also block the infection of SARS-CoV-2 by interacting with residue Lys353 in the peptidase domain of ACE2.The transmembrane protease serine 2(TMPRSS2)inhibitors Camostat mesylate and Proxalutamide inhibit infection by blocking TMPRSS2 mediates viral membrane fusion.The main protease inhibitor Paxlovid and RNA-dependent RNA polymerase inhibitor Azvudine have been approved for treatment of COVID-19 patients.This review summarizes the current research status of neutralizing antibodies and small molecule inhibitors and prospects for their application.We expect to provide more valuable information for further studies in this field.

Fluoxetine and Sertraline Potently Neutralize the Replication of Distinct SARS-CoV-2 Variants

Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model

Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro

Discovery of Potential Anti-Sars-cov-2 Drugs Based on Large-Scale Screening in Vitro and Effect Evaluation in Vivo

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants

Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection

AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults

Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein

The Research Status of Novel Coronavirus Antibodies and Small Molecule Inhibitors

The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo

The Acid Ceramidase Is a SARS-CoV-2 Host Factor

FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms

Antimalarial Artefenomel Inhibits Human SARS-CoV-2 Replication in Cells while Suppressing the Receptor ACE2

Azole derivatives inhibit the binding of the RBD domain of SARS-Cov-2 against host ACE2 in in vitro assays

Characterization of the symmetrical benzimidazole twin drug TL1228: the role as viral entry inhibitor for fighting COVID-19

Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing

A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection